New LaunchMay 15, 2026, 07:32 AM
BriaCell Expands into Ovarian Cancer with Bria-OVA+ Immunotherapy
AI Summary
BriaCell Therapeutics Corp. announced its expansion into women's health, focusing on ovarian cancer with its new personalized immunotherapy candidate, Bria-OVA+. This strategic move follows encouraging efficacy and tolerability data from the company's Phase 2 study in metastatic breast cancer. Bria-OVA+ is designed as a next-generation, off-the-shelf, cell-based immunotherapy to address the significant unmet medical need in ovarian cancer, which remains the deadliest gynecologic cancer. The company has initiated development activities for Bria-OVA+ after licensing necessary cell lines.
Key Highlights
- BriaCell expands pipeline into gynecologic cancers, starting with ovarian cancer.
- Introduces Bria-OVA+, a next-generation personalized immunotherapy for ovarian cancer.
- Expansion builds on encouraging efficacy and tolerability data from Phase 2 breast cancer study.
- Bria-OVA+ designed with additional immune-stimulating components for enhanced anti-tumor activity.
- Ovarian cancer is the deadliest gynecologic cancer, with 12,450 U.S. deaths projected in 2026.
- Company licensed ovarian cancer cell lines and commenced Bria-OVA+ development activities.
- Preclinical data for Bria-BRES+ showed activation of adaptive and innate immunity.
Price Impact
More from BCTX